Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01428362 · ClinicalTrials.gov registry record · Phase 2

VI-1121 for the Treatment Alzheimer's Disease

A Phase 2 study of Alzheimers Disease, sponsored by VIVUS.

Completed
Registry status
Phase 2
Development phase
61
Enrollment target
11
Study locations

NCT01428362: Completed Phase 2 study of Alzheimers Disease, sponsored by VIVUS.

NCT01428362 is a Phase 2 study of Alzheimers Disease that has completed, run by VIVUS. The registered enrollment target is 61 participants, below the 3,926-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (98% lower). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01428362, a Phase 2 study of Alzheimers Disease, has completed, sponsored by VIVUS.

COMPLETED
Registry status
Phase 2
Development phase
61 participants
Enrollment target
11
Study locations

Study Summary

The purpose of this study is to determine whether VI-1121 is safe, well tolerated, and effective as a daily treatment for Alzheimer's disease that is worsening despite current treatment.

Conditions Studied

Alzheimers Disease

Interventions

  • DRUG Placebo
  • DRUG VI-1121

Study Locations (11)

California

  • - San Francisco
  • - Santa Monica

North Carolina

  • - Durham
  • - Raleigh

Florida

  • - Sunrise

Kentucky

  • - Louisville

Nevada

  • - Las Vegas

New Jersey

  • - Toms River

New York

  • - New Windsor

Ohio

  • - Toledo

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2011-08
Est. Completion 2013-08
Phase Phase 2
VIVUS

35 total trials

What the finished NCT01428362 record still lists

NCT01428362 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 3,926-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01428362 lists 11 locations in 9 states (California, North Carolina, Florida).

Frequently Asked Questions

What is clinical trial NCT01428362 about?

NCT01428362 is a clinical study titled "VI-1121 for the Treatment Alzheimer's Disease". The purpose of this study is to determine whether VI-1121 is safe, well tolerated, and effective as a daily treatment for Alzheimer's disease that is worsening despite current treatment.

What is the current status of trial NCT01428362?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2011-08. Estimated completion is 2013-08.

What conditions does trial NCT01428362 study?

This clinical trial studies the following conditions: Alzheimers Disease.

What interventions are being tested in trial NCT01428362?

The interventions under investigation include: Placebo (DRUG), VI-1121 (DRUG).

Who is sponsoring clinical trial NCT01428362?

This trial is sponsored by VIVUS, which has 35 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01428362 being conducted?

This trial has 11 study locations across California, Florida, Kentucky, Nevada, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimers Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01428362's enrollment target sits among peer trials

61 85th of 147 higher than 63 of 147 other Alzheimers Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alzheimers Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04115306 · 61 participants · Phase 1

    Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

  • NCT05070845 · 61 participants · Phase 2

    Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

  • NCT05187832 · 61 participants · Phase 1

    A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

  • NCT05269316 · 61 participants · Phase 1

    Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01428362, the US trial registry maintained by the National Library of Medicine. NCT01428362 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.